Abstract
Much progress has been made in the clinical, biological and technical aspects of the T-cell-depleted full-haplotype mismatched transplants for acute leukaemia. Our experience demonstrates that infusing a megadose of extensively T-cell-depleted haematopoietic peripheral blood stem cells after an immuno-myeloablative conditioning regimen in acute leukaemia patients ensures sustained engraftment with minimal GvHD without the need of any post-transplant immunosuppressive treatment. Since our first successful pilot study, our efforts have concentrated on developing new conditioning regimens, optimising the graft processing and improving the post-transplant immunological recovery. The results we have so far achieved in more than 200 high-risk acute leukaemia patients show that haploidentical transplantation is now a clinical reality. Because virtually all patients have a mismatched family member, who is immediately available, mismatched transplantation should be offered as a viable option to high-risk acute leukaemia patients who do not have, or cannot find, a matched donor.
Original language | English (US) |
---|---|
Pages (from-to) | 8-12 |
Number of pages | 5 |
Journal | Blood Cells, Molecules, and Diseases |
Volume | 40 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2008 |
Externally published | Yes |
Keywords
- Haploidentical transplant
- High risk acute leukaemia
- Megadose of CD34 cells
- NK-cell alloreactivity
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
- Hematology
- Cell Biology